Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Top Cited Papers
- 15 January 2005
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 174 (2), 817-826
- https://doi.org/10.4049/jimmunol.174.2.817
Abstract
B cell immunotherapy has emerged as a mainstay in the treatment of lymphomas and autoimmune diseases. Although the microenvironment has recently been demonstrated to play critical roles in B cell homeostasis, its contribution to immunotherapy is unknown. To analyze the in vivo factors that regulate mechanisms involved in B cell immunotherapy, we used a murine model for human CD20 (hCD20) expression in which treatment of hCD20+ mice with anti-hCD20 mAbs mimics B cell depletion observed in humans. We demonstrate in this study that factors derived from the microenvironment, including signals from the B cell-activating factor belonging to the TNF family/BLyS survival factor, integrin-regulated homeostasis, and circulatory dynamics of B cells define distinct in vivo mechanism(s) and sensitivities of cells in anti-hCD20 mAb-directed therapies. These findings provide new insights into the mechanisms of immunotherapy and define new opportunities in the treatment of cancers and autoimmune diseases.Keywords
This publication has 38 references indexed in Scilit:
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyThe Journal of Experimental Medicine, 2004
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart RateJournal of Biological Chemistry, 2004
- FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood, 2004
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- Effect of anti‐CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrixCytometry Part A, 2003
- Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor AgonistsScience, 2002
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985